Jundishapur Journal of Microbiology

Published by: Kowsar

In Vitro Evaluation of Influenza M2 and Leishmania major HSP70 (221-604) Chimer Protein

Fatemeh Fotouhi 1 , * , Behrokh Farahmand 1 , Behnaz Heidarchi 1 , Maryam Esghaei 2 , Sima Rafati 3 and Masoumeh Tavassoti Kheiri 1
Authors Information
1 Influenza Research Lab, Department of Virology, Pasteur Institute of Iran, Tehran, IR Iran
2 Virology Department, Iran University of Medical Sciences, Tehran, IR Iran
3 Molecular Immunology and Vaccine Research Lab, Department of Immunology, Pasteur Institute of Iran, Tehran, IR Iran
Article information
  • Jundishapur Journal of Microbiology: September 01, 2014, 7 (9); e11812
  • Published Online: September 1, 2014
  • Article Type: Research Article
  • Received: May 6, 2013
  • Revised: June 24, 2013
  • Accepted: July 11, 2013
  • DOI: 10.5812/jjm.11812

To Cite: Fotouhi F, Farahmand B, Heidarchi B, Esghaei M, Rafati S, et al. In Vitro Evaluation of Influenza M2 and Leishmania major HSP70 (221-604) Chimer Protein, Jundishapur J Microbiol. 2014 ; 7(9):e11812. doi: 10.5812/jjm.11812.

Abstract
Copyright © 2014, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine. 2004; 22(23-24): 2993-3003[DOI][PubMed]
  • 2. Mozdzanowska K, Zharikova D, Cudic M, Otvos L, Gerhard W. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse. Virol J. 2007; 4: 118[DOI][PubMed]
  • 3. Epstein SL, Tumpey TM, Misplon JA, Lo CY, Cooper LA, Subbarao K, et al. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis. 2002; 8(8): 796-801[DOI][PubMed]
  • 4. Rao SS, Kong WP, Wei CJ, Van Hoeven N, Gorres JP, Nason M, et al. Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret. PLoS One. 2010; 5(3)[DOI][PubMed]
  • 5. Okuda K, Ihata A, Watabe S, Okada E, Yamakawa T, Hamajima K, et al. Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. Vaccine. 2001; 19(27): 3681-91[PubMed]
  • 6. Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR, Dean HJ. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine. 2006; 24(21): 4475-81[DOI][PubMed]
  • 7. Wu F, Huang JH, Yuan XY, Huang WS, Chen YH. Characterization of immunity induced by M2e of influenza virus. Vaccine. 2007; 25(52): 8868-73[DOI][PubMed]
  • 8. Treanor JJ, Tierney EL, Zebedee SL, Lamb RA, Murphy BR. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol. 1990; 64(3): 1375-7[PubMed]
  • 9. Zebedee SL, Lamb RA. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol. 1988; 62(8): 2762-72[PubMed]
  • 10. Zhang X, Yu C, Zhao J, Fu L, Yi S, Liu S, et al. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice. J Gene Med. 2007; 9(8): 715-26[DOI][PubMed]
  • 11. Li X, Yang X, Li L, Liu H, Liu J. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HBV DNA vaccine. Vaccine. 2006; 24(16): 3321-31[DOI][PubMed]
  • 12. Finotti P, Pagetta A. A heat shock protein70 fusion protein with alpha1-antitrypsin in plasma of type 1 diabetic subjects. Biochem Biophys Res Commun. 2004; 315(2): 297-305[DOI][PubMed]
  • 13. Hirayama E, Atagi H, Hiraki A, Kim J. Heat shock protein 70 is related to thermal inhibition of nuclear export of the influenza virus ribonucleoprotein complex. J Virol. 2004; 78(3): 1263-70[PubMed]
  • 14. Kaur J, Kaur T, Kaur S. Studies on the protective efficacy and immunogenicity of Hsp70 and Hsp83 based vaccine formulations in Leishmania donovani infected BALB/c mice. Acta Trop. 2011; 119(1): 50-6[DOI][PubMed]
  • 15. Henderson B, Pockley AG. Molecular chaperones and protein-folding catalysts as intercellular signaling regulators in immunity and inflammation. J Leukoc Biol. 2010; 88(3): 445-62[DOI][PubMed]
  • 16. Kilic A, Mandal K. Heat shock proteins: pathogenic role in atherosclerosis and potential therapeutic implications. Autoimmune Dis. 2012; 2012: 502813[DOI][PubMed]
  • 17. Rafati S, Gholami E, Hassani N, Ghaemimanesh F, Taslimi Y, Taheri T, et al. Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients. Vaccine. 2007; 25(21): 4159-69[DOI][PubMed]
  • 18. Esghaei M, Monavari SH, Tavassoti-Kheiri M, Shamsi-Shahrabadi M, Heydarchi B, Farahmand B, et al. Expression of the influenza M2 protein in three different eukaryotic cell lines. J Virol Methods. 2012; 179(1): 161-5[DOI][PubMed]
  • 19. De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A, et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology. 2005; 337(1): 149-61[DOI][PubMed]
  • 20. Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine. 1995; 13(15): 1399-402[PubMed]
  • 21. Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis. 2007; 13(3): 426-35[DOI][PubMed]
  • 22. Jimenez GS, Planchon R, Wei Q, Rusalov D, Geall A, Enas J, et al. Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum Vaccin. 2007; 3(5): 157-64[PubMed]
  • 23. Li J, Ye ZX, Li KN, Cui JH, Li J, Cao YX, et al. HSP70 gene fused with Hantavirus S segment DNA significantly enhances the DNA vaccine potency against hantaviral nucleocapsid protein in vivo. Vaccine. 2007; 25(2): 239-52[DOI][PubMed]
  • 24. Li J, Li KN, Gao J, Cui JH, Liu YF, Yang SJ. Heat shock protein 70 fused to or complexed with hantavirus nucleocapsid protein significantly enhances specific humoral and cellular immune responses in C57BL/6 mice. Vaccine. 2008; 26(25): 3175-87[DOI][PubMed]
  • 25. Jazi MH, Dabaghian M, Tebianian M, Gharagozlou MJ, Ebrahimi SM. In vivo electroporation enhances immunogenicity and protection against influenza A virus challenge of an M2e-HSP70c DNA vaccine. Virus Res. 2012; 167(2): 219-25[DOI][PubMed]
  • 26. Shaw A. Conserved proteins as potential universal vaccines.Influenza vaccines for the future. 2011; : 313-25[DOI]
  • 27. Bommakanti G, Lu X, Citron MP, Najar TA, Heidecker GJ, ter Meulen J, et al. Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge. J Virol. 2012; 86(24): 13434-44[DOI][PubMed]
  • 28. Varadarajan R, Sharma D, Chakraborty K, Patel M, Citron M, Sinha P, et al. Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design. J Virol. 2005; 79(3): 1713-23[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments